Insider Trading February 13, 2026

Viavi Solutions SVP Disposes $369,627 in Shares; Company Posts Q2 Beat

Luke Scrivanich sold 13,901 shares while Viavi reported stronger-than-expected Q2 fiscal 2026 results

By Marcus Reed VIAV
Viavi Solutions SVP Disposes $369,627 in Shares; Company Posts Q2 Beat
VIAV

Viavi Solutions Inc. senior vice president Luke M. Scrivanich sold 13,901 shares on February 13, 2026, for $26.59 per share, realizing $369,627. After the sale he directly holds 49,980 shares, a total that includes an exempt ESPP purchase of 2,061 shares on January 30, 2026. The transaction was disclosed on a Form 4 with the Securities and Exchange Commission. Separately, Viavi reported fiscal 2026 second-quarter results that beat expectations on both EPS and revenue.

Key Points

  • SVP Luke M. Scrivanich sold 13,901 Viavi Solutions shares on February 13, 2026, at $26.59 per share, totaling $369,627.
  • After the transaction, Scrivanich directly holds 49,980 shares, which includes a 2,061-share ASPP exempt purchase on January 30, 2026.
  • Viavi Solutions reported Q2 fiscal 2026 EPS of $0.22 (versus $0.19 expected) and revenue of $369.3 million (versus $365.25 million expected); the company’s results were reported as being well-received by investors.

Luke M. Scrivanich, who serves as Senior Vice President and General Manager for OSP at Viavi Solutions Inc (NASDAQ:VIAV), completed a sale of common stock on February 13, 2026. The filing shows 13,901 shares were sold at $26.59 per share, producing total proceeds of $369,627.

Following that disposition, Scrivanich is recorded as directly owning 49,980 shares of Viavi Solutions common stock. That total explicitly incorporates an exempt purchase of 2,061 shares made under the company's Employee Stock Purchase Plan (ESPP) on January 30, 2026.

The insider sale was disclosed in a Form 4 filing submitted to the Securities and Exchange Commission, as required for certain transactions by corporate insiders.


In a separate corporate update, Viavi Solutions reported fiscal second-quarter results for 2026 that exceeded market forecasts. The company posted earnings per share of $0.22, versus a consensus expectation of $0.19, representing a 15.79% earnings surprise. Revenue for the quarter was reported at $369.3 million, modestly above the anticipated $365.25 million. According to the report, these results were well-received by investors.

The combined disclosures - the insider sale and the quarterly financial report - were recorded as recent updates relating to Viavi Solutions. The Form 4 filing documents the specific details of the share sale, while the company's quarterly release provides the headline financial metrics.


Below are the core facts from the filings and corporate disclosure, presented without extrapolation beyond the reported information:

  • Insider transaction: 13,901 shares sold on February 13, 2026, at $26.59 per share, totaling $369,627.
  • Post-sale holdings: Scrivanich directly owns 49,980 shares, which include a 2,061-share ESPP exempt purchase dated January 30, 2026.
  • Regulatory disclosure: The sale was reported on a Form 4 filed with the U.S. Securities and Exchange Commission.
  • Quarterly results: Q2 fiscal 2026 EPS of $0.22 versus a $0.19 estimate (15.79% surprise); revenue of $369.3 million versus an expected $365.25 million.

The information above is limited to what was provided in the filings and the company’s financial release; no additional motives, intentions, or forward-looking guidance were included in those disclosures.

Risks

  • The filings do not specify the reason for the insider sale; no motive or use of proceeds is disclosed in the Form 4.
  • The article does not provide any forward guidance or longer-term outlook from the company beyond the single-quarter results.
  • The reported holdings after the sale are limited to direct ownership; the filing does not detail any other forms of beneficial ownership or future transactions.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026